Guidelines of european society of cardiology on managementof acute ST-elevation myocardial infarctionof 2017: what is new?
Authors:
Company: Cardiology Chair of Moscow State University of Medicine and Dentistry named after A.I. Evdokimov of Ministry of Health of the Russian Federation; Delegatskaya ulitsa, 20/1, Moscow, 127473, Russian Federation
For correspondence: Sign in or register.
DOI:
For citation: Shpektor A.V. Guidelines of European Society of Cardiology on management of acute ST-elevation myocardial infarction of 2017: what is new? Kreativnaya Kardiologiya (Creative Cardiology). 2017; 11 (4): 299-303 (in Russ.). DOI: 10.24022/1997-3187-2017-11-4-299-303.
Received / Accepted: 14.11.2017/21.11.2017
Keywords: acute myocardial infarction percutaneous coronary intervention desagregation therapy
Abstract
The article lights an updated European Society of Cardiology guidelines on acute ST-elevation myocardial infarction, published in 2017. Changes have been made in myocardial revascularization and drug therapy are discussed. The article will help to be up to date for practicing cardiologists, therapists and interventional specialists working in this field.
References
Ibanez B., James S., Ag S. et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of) ESC Clinical Practice Guidelines 2017. Eur. Heart J. 2017: 1–66. DOI: 10.1093/eurheartj/ehx393.
Steg Ph.G., James S., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012; (33): 2569–619. DOI: 10.1093/eurheartj/ehs215.
Leonardi S., Frigoli E., Rothenbuhler M. et al. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ. 2016; 354: 4935. DOI: 10.1136/bmj.i4935.
Raber L., Kelbaek H., Ostojic M. et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012; 308 (8): 777–87. DOI: 10.1001/jama.2012.10065.
Sabate M., Brugaletta S., Cequier A. et al. Clinical outcomes in patients with STsegment elevation myocardial infarction treated with everolimuseluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomized trial. Lancet. 2016; 387 (10016): 357–66. DOI: 10.1016/S0140-6736(15)00548-6.
Bonaa K.H., Mannsverk J., Wiseth R. et al. Drugeluting or bare-metal stents for coronary artery disease. N. Engl. J. Med. 2016; 375 (13): 1242–52. DOI: 10.1056/NEJMoa1607991.
Sorajja P., Gersh B.J., Cox D.A. et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur. Heart J. 2007; 28 (14): 1709–16.
Cavender M.A., Milford-Beland S., Roe M.T. et al. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am. J. Cardiol. 2009; 104 (4): 507–13. DOI: 10.1016/j.amjcard.2009.04.016.
Hannan E.L., Samadashvili Z., Walford G. et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronaryintervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc. Interv. 2010; 3 (1): 22–31. DOI: 10.1016/j.jcin.2009.10.017.
Jolly S.S., Cairns J.A., Yusuf S. et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N. Engl. J. Med. 2015; 372 (15): 1389–98. DOI: 10.1056/NEJMoa1415098.
Frobert O., Lagerqvist B., Olivecrona G.K. et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N. Engl. J. Med. 2013; 369 (17): 1587–97. DOI: 10.1056/NEJMoa1308789.
Kelbaek H., Hofsten D.E., Kober L. et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an openlabel, randomized controlled trial. Lancet. 2016;
